BrainStorm Cell Therapeutics Announces Aggregate of $400,000 in Private Placements Priced at Premium to Market

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a prominent developer of adult stem cell therapies for neurodegenerative diseases, has successfully completed a private placement fundraising initiative, securing gross proceeds of $400,000. The transaction, finalized in May 2026, was priced at $0.95 per share, representing a 37.6% premium over the previous day's closing price of $0.69. This strategic move is part of BrainStorm's ongoing efforts to bolster its financial position ahead of its Phase 3b ENDURANCE trial.

The private placement involved two separate transactions that collectively raised $200,000, with the first closing on May 11, 2026, and the final placement concluding on May 18, 2026. Investors in this placement will also receive 120% warrant coverage, with an exercise price set at $1.45 per share, valid for five years from the issuance date. This financing builds upon a prior capital raise of $2.0 million completed in February 2026, indicating a sequential increase in both share and warrant prices, which reflects the market's growing confidence in BrainStorm's reduced risk profile and long-term potential.

BrainStorm's proprietary NurOwn® platform, which utilizes autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), is central to the company’s mission to address debilitating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The company has made significant strides in its clinical programs, having completed a Phase 3 trial for ALS and preparing for a second Phase 3b trial under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration (FDA). This ongoing clinical development is critical, as it aims to provide new therapeutic options for patients facing progressive neurological conditions.

The successful capital raise at a premium price is indicative of investor confidence in BrainStorm's scientific foundation and the potential of its therapies. Management has articulated that this financing is not only intended to extend the company's operational runway but also to support its regulatory momentum without imposing undue dilution on existing shareholders. The strategic approach to securing funds at a premium underscores the company's focus on maintaining a robust capital structure while exploring various funding avenues for its upcoming clinical trials.

Looking ahead, the implications of this fundraising extend beyond BrainStorm itself, as it reflects broader trends in the biotech sector where companies are increasingly seeking innovative financing solutions to support costly clinical trials. As the market evolves, the ability to attract investment at favorable terms will be crucial for firms engaged in developing cutting-edge therapies. The success of BrainStorm's recent fundraising efforts may encourage other companies in the sector to pursue similar strategies, potentially leading to increased activity in private placements and other financing mechanisms within the biotechnology landscape.